AA
TCRT icon

ALPS Advisors’s Alaunos Therapeutics TCRT Stock Holding History

ALPS Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,589
Closed -$1.4M – 918
2021
Q1 		$1.4M Buy
2,589
+8
+0.3% +$4.98K 0.01% 359
2020
Q4 		$975K Buy
+2,581
New +$1.03M 0.01% 391

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

ALPS Advisors's TCRT Position: Q2 2021 in Review

ALPS Advisors sold out of Alaunos Therapeutics (TCRT) in Q2 2021, closing a stake of 2,589 shares — an estimated $1.4M sold.

ALPS Advisors first reported a position in TCRT in Q4 2020 and held it in 2 quarters. The position peaked at $1.4M in Q1 2021. 155 funds tracked by Wall St. Rank hold TCRT as of Q2 2021.

  • ALPS Advisors reported no remaining Alaunos Therapeutics position as of Q2 2021 after selling out during the quarter.
  • ALPS Advisors sold 2,589 Alaunos Therapeutics shares in Q2 2021, an estimated $1.4M.
  • ALPS Advisors first reported a position in Alaunos Therapeutics in Q4 2020 and held it in 2 quarters.
  • ALPS Advisors's Alaunos Therapeutics position peaked at $1.4M in Q1 2021.
  • 155 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2021.

Based on ALPS Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.